Polo-like kinase 4 inhibition: a strategy for cancer therapy?

Cancer Cell. 2014 Aug 11;26(2):151-3. doi: 10.1016/j.ccr.2014.07.017.

Abstract

In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.

Publication types

  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Breast Neoplasms / enzymology*
  • Female
  • Humans
  • Indazoles / pharmacology*
  • Indoles / pharmacology*
  • Protein-Serine-Threonine Kinases / metabolism*

Substances

  • 2-(3-(4-((2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro(cyclopropane-1,3'-indolin)-2'-one
  • Antineoplastic Agents
  • Indazoles
  • Indoles
  • PLK4 protein, human
  • Protein-Serine-Threonine Kinases